<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="1659">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on October 07, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04575545</url>
  </required_header>
  <id_info>
    <org_study_id>2020-A02018-31</org_study_id>
    <nct_id>NCT04575545</nct_id>
  </id_info>
  <brief_title>Prevalence of COVID-19 Infection in a Cohort of Patients Infected by the HIV and Patients Taking PrEP</brief_title>
  <official_title>Prevalence of COVID-19 Infection in a Cohort of Patient Infected by the HIV and Patients Taking PrEP Pre-exposure Prophylaxis</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Hôpital Européen Marseille</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Hôpital Européen Marseille</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of the study is to assess seroprevalence of COVID-19 infection in a cohort of HIV
      + patients and in a cohort of patients taking PrEP by emtricitabine / tenofovir.
    </textblock>
  </brief_summary>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">October 2020</start_date>
  <completion_date type="Anticipated">April 2022</completion_date>
  <primary_completion_date type="Anticipated">March 2021</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>% of patients with positive serological tests for covid-19</measure>
    <time_frame>3 months</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Presence and quantification of CD4 / CD8 reactivity to COVID-19 epitopes in patient with positive and negative serological tests for covid-19</measure>
    <time_frame>3 months</time_frame>
    <description>% of anti-covid positive cells</description>
  </secondary_outcome>
  <number_of_groups>2</number_of_groups>
  <enrollment type="Anticipated">600</enrollment>
  <condition>Covid19</condition>
  <condition>Virus-HIV</condition>
  <arm_group>
    <arm_group_label>HIV positive patients</arm_group_label>
  </arm_group>
  <arm_group>
    <arm_group_label>Patients taking PrEP</arm_group_label>
  </arm_group>
  <intervention>
    <intervention_type>Diagnostic Test</intervention_type>
    <intervention_name>Serology test for COVID-19</intervention_name>
    <description>ELISA test</description>
    <arm_group_label>HIV positive patients</arm_group_label>
    <arm_group_label>Patients taking PrEP</arm_group_label>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        patients infected by the HIV on treatment and patients taking PreP
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Aged ≥ 18 years

          -  patients infected by the HIV on treatment

          -  patients taking PreP (Pre-exposure prophylaxis (PrEP))

          -  Being affiliated with or benefiting from a social security scheme

        Exclusion Criteria:

          -  Subject to a measure for the protection of justice
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Patrick PHILIBERT</last_name>
    <role>Principal Investigator</role>
    <affiliation>Hôpital Europeen Marseille</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Myriam BENNANI</last_name>
    <phone>0413428351</phone>
    <email>m.bennani@hopital-europeen.fr</email>
  </overall_contact>
  <location>
    <facility>
      <name>BENNANI</name>
      <address>
        <city>Marseille</city>
        <zip>13003</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <verification_date>September 2020</verification_date>
  <study_first_submitted>October 2, 2020</study_first_submitted>
  <study_first_submitted_qc>October 2, 2020</study_first_submitted_qc>
  <study_first_posted type="Estimate">October 5, 2020</study_first_posted>
  <last_update_submitted>October 2, 2020</last_update_submitted>
  <last_update_submitted_qc>October 2, 2020</last_update_submitted_qc>
  <last_update_posted type="Estimate">October 5, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Infection</mesh_term>
    <mesh_term>Acquired Immunodeficiency Syndrome</mesh_term>
    <mesh_term>HIV Infections</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

